bluebird bio (NASDAQ:BLUE) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report report published on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on the company. Robert W. Baird decreased their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. Wells Fargo & Company lowered their target price on bluebird bio from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Wednesday, September 25th. JPMorgan Chase & Co. cut bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th. Barclays decreased their price target on bluebird bio from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Friday, November 15th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.03.

bluebird bio Trading Up 105.4 %

bluebird bio stock opened at $0.74 on Wednesday. The stock has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.73. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The stock has a market cap of $143.17 million, a PE ratio of -0.39 and a beta of 0.72. bluebird bio has a one year low of $0.29 and a one year high of $5.53.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The company had revenue of $18.57 million for the quarter. On average, research analysts anticipate that bluebird bio will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On bluebird bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of bluebird bio by 19.6% in the 1st quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock worth $13,438,000 after buying an additional 1,723,081 shares during the period. Geode Capital Management LLC increased its holdings in bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after purchasing an additional 166,771 shares in the last quarter. State Street Corp increased its holdings in bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares in the last quarter. FMR LLC increased its holdings in bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after purchasing an additional 186,903 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in bluebird bio by 315.3% in the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock valued at $1,223,000 after purchasing an additional 1,013,144 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.